Lipid-related FABP5 activation of tumor-associated monocytes fosters immune privilege via PD-L1 expression on Treg cells in hepatocellular carcinoma.
Jin LiuBinwen SunKun GuoZhou YangYidan ZhaoMingwei GaoZeli YinKeqiu JiangChengyong DongZhenming GaoMingliang YeJing LiuLiming WangPublished in: Cancer gene therapy (2022)
Monocytes/macrophages, a plastic and heterogeneous cell population of the tumor microenvironment (TME), can constitute a major component of most solid tumors. Under the pressure of rapid proliferation of the tumor, monocytes/macrophages can be educated and foster immune tolerance via metabolic reprogramming. Our studies have shown that the activation of FABP5, a lipid-binding protein, decreases the rate of β-oxidation causing the accumulation of lipid droplets in monocytes. We found that hepatocellular carcinoma cells (HCC) increased IL-10 secretion by monocytes, which depended on the expression of FABP5 and suppressing of the PPARα pathway. Moreover, the elevated level of IL-10 promotes PD-L1 expression on Treg cells via the JNK-STAT3 pathway activation. We also observed that elevation of FABP5 in monocytes was negatively related to HCC patients' overall survival time. Thus, FABP5 promotes monocyte/macrophage lipid accumulation, fosters immune tolerance formation, and might represent itself as a therapeutic target in both tumor-associated monocytes (TAMs) and cancer cells.
Keyphrases
- binding protein
- dendritic cells
- peripheral blood
- induced apoptosis
- signaling pathway
- end stage renal disease
- newly diagnosed
- cell cycle arrest
- chronic kidney disease
- poor prognosis
- single cell
- oxidative stress
- stem cells
- ejection fraction
- insulin resistance
- nitric oxide
- immune response
- cell proliferation
- prognostic factors
- cell therapy
- mesenchymal stem cells
- long non coding rna
- skeletal muscle
- patient reported outcomes
- sensitive detection